A retrospective review of patients with atypical femoral fractures while on long-term bisphosphonates: Including pertinent biochemical and imaging studies

Endocrine Practice

Volumn 19, Issue 3, 2013, Pages 456-461

  Markman, Lisa H ^a   Allison, Mary B ^a   Rosenberg, Zehava S ^a   Vieira, Renata L ^a   Babb, James S ^a   Tejwani, Nirmal C ^a   Im, Shelly A ^a   Peck, Valerie ^a  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; ALENDRONIC ACID; ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; PARATHYROID HORMONE;

AFRICAN AMERICAN; AGE; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ASIAN; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; CALCIUM BLOOD LEVEL; CAUCASIAN; COMORBIDITY; FEMALE; FEMUR SUBTROCHANTERIC FRACTURE; FRAGILITY FRACTURE; GENDER; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID HORMONE BLOOD LEVEL; PROTEIN BLOOD LEVEL; PROTEIN URINE LEVEL; RETROSPECTIVE STUDY; REVIEW; TREATMENT DURATION; VITAMIN BLOOD LEVEL;

AGED; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; FEMALE; FEMORAL FRACTURES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; VITAMIN D;

EID: 84880123809     PISSN: 1530891X     EISSN: 19342403     Source Type: Journal    
DOI: 10.4158/EP12179.OR     Document Type: Review

References (21)

1. Liberman UA, Weiss SR, Bröll J, et al. Effect of oral alendronate on bone mineral density an. The incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333:1437-1443.
2. Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanisms of action and role in clinical practice. Mayo Clin Proc. 2008;83:1032-1045.
3. Shane E, Burr D, Ebeling PR, et al. Atypical subtrochanteric diaphyseal femoral fractures: report of a task force o. The American Society for Bone and Mineral Research. J Bone Miner Res. 2010;25:2267-2294.
4. Goddard MS, Reid KR, Johnston JC, Khanuja HS. Atraumatic bilateral femur fracture in long-term bisphosphonate use. Orthopedics. 2009;32:8.
5. Lee P, Seibel MJ. More on atypical fractures o. The femoral diaphysis. N Engl J Med. 2008;359:317-318.
6. Lenart BA, Lorich DG, Lane JM. Atypical fractures o. The femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med. 2008;358:1304-1306.
7. Sayed-Noor AS, Sjödén GO. Subtrochanteric displaced insufficiency fracture after long-term alendronate therapy-a case report. Acta Orthop. 2008;79:565-567.
8. Vasikaran SD. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case-control study. Osteoporos Int. 2009;20:1457-1458.
9. Tang SY, Zeenath U, Vashishth D. Effects of non-enzymatic glycation on cancellous bone fragility. Bone. 2007; 40:1144-1151.
10. Vashishth D. Advanced glycation end-products and bone fractures. IBMS BoneKEy. 2009;6:268-278. Available at: http://www.nature.com/bonekey/knowledge environment/2009/0908/bonekey20090390/full/bonekey 20090390.html.
11. Giusti A, Hamdy NA, Papapoulos SE. Atypical fractures o. The femur and bisphosphonate therapy: a systematic review of case/case series studies. Bone. 2010;47:169-180.
12. Donnelly E, Meredith DS, Nguyen JT, et al. Reduced cortical bone compositional heterogeneity with bisphosphonate treatment in postmenopausal women with intertrochanteric and subtrochanteric fractures. J Bone Miner Res. 2012;27:672-678.
13. Donnelly E, Meredith DS, Nguyen JT, Boskey AL. Bone tissue composition varies across anatomic sites i. The proximal femur an. The iliac crest. J Orthop Res. 2012;30: 700-706.
14. Rosenberg ZS, La Rocca Vieira R, Chan SS, et al. Bisphosphonate-related complete atypical subtrochanteric femoral fractures: diagnostic utility of radiography. Am J Roentgenol. 2011;197:954-960.
15. Goh SK, Yang KY, Koh JS, et al. Subrochanteric insufficiency fractures in patients on alendronate therapy: a caution. J Bone Joint Surg Br. 2007;89:349-353.
16. Kwek EB, Goh SK, Koh JS, Png MA, Howe TS. An emerging pattern of subtrochanteric stress fractures: a long-term complication of alendronate therapy Injury. 2008;39:224-231.
17. Neviaser AS, Lane JM, Lenart BA, Edobor-Osula F, Lorich DG. Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma. 2008;22:346-350.
18. Odvina CV, Levy S, Rao S, Zerwekh JE, Rao DS. Unusual mid-shaft fractures during long-term bisphosphonate therapy. Clin Endocrinol (Oxf). 2010;72:161-168.
19. Lenart BA, Neviaser AS, Lyman S, et al. Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int. 2009;20: 1353-1362.
20. Johnell O, Kanis JA. An estimate o. The worldwide prevalence and disability associated with osteoporotic fractures. Osteoporos Int. 2006;17:1726-1733.
21. Feldstein AC, Black D, Perrin N, et al. Incidence and demography of femur fractures with and without atypical features. J Bone Miner Res. 2012;27:977-986.